Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects

por Linnebjerg, Helle, LaBell, Elizabeth Smith, Dellva, Mary Anne, Coutant, David E., Leohr, Jennifer
Publicado 2020

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus

por Linnebjerg, Helle, Lam, Eric Chen Quin, Zhang, Xin, Seger, Mary E., Coutant, David, Chua, Laiyi, Kapitza, Christoph, Heise, Tim
Publicado 2016

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog(®) (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Contro...

por Linnebjerg, Helle, Zhang, Qianyi, LaBell, Elizabeth, Dellva, Mary Anne, Coutant, David E., Hövelmann, Ulrike, Plum-Mörschel, Leona, Herbrand, Theresa, Leohr, Jennifer
Publicado 2020

Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, cross...

por Heise, Tim, Linnebjerg, Helle, Coutant, David, LaBell, Elizabeth, Zijlstra, Eric, Kapitza, Christoph, Bue‐Valleskey, Juliana, Zhang, Qianyi, Dellva, Mary Anne, Leohr, Jennifer
Publicado 2020

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog(®) (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study

por Leohr, Jennifer, Dellva, Mary Anne, Coutant, David E., LaBell, Elizabeth, Heise, Tim, Andersen, Grit, Zijlstra, Eric, Hermanski, Lidia, Nosek, Leszek, Linnebjerg, Helle
Publicado 2020

LY3127760, a Selective Prostaglandin E4 (EP4) Receptor Antagonist, and Celecoxib: A Comparison of Pharmacological Profiles

por Jin, Yan, Smith, Claire, Hu, Leijun, Coutant, David E., Whitehurst, Kelly, Phipps, Krista, McNearney, Terry Ann, Yang, Xiao, Ackermann, Bradley, Pottanat, Thomas, Landschulz, William
Publicado 2017